Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies

Inclusion Criteria: * Female patients with the following histologically confirmed advanced gynaecological malignancies: epithelial ovarian cancer, endometrial carcinoma, uterine sarcoma, mixed Müllerian tumour, fallopian tube carcinoma, primary peritoneal carcinoma, cervical carcinoma or vulvular carcinoma * Metastatic disease or locally advanced disease that is not resectable with curative intention * Indication for combination chemotherapy with paclitaxel/carboplatin as judged by the investigator * Age 18 years or older * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Life expectancy of at least 6 months * Written informed consent that is not consistent with ICH-GCP (International Conference on Harmonisation - Good Clinical Practice) guidelines and local requirements Exclusion Criteria: * Participation in another clinical study within the past 4 weeks before start of therapy or concomitantly with this study * Radiotherapy within 4 weeks before the start of therapy * Chemotherapy, immunotherapy or hormonal therapy (with the exception of hormonal replacement therapy) within 4 weeks before the start of the therapy * Patients with germ cell tumours, early stage ovarian cancer (Fédération Internationale de Gynécologie et d'Obstétrique \[FIGO\] stage I-IIA), primary cervical cancer (FIGO I-III), primary endometrial cancer (FIGO I-III) or borderline tumours * Patients with known brain metastases * Symptomatic bowel obstruction or known or suspected malabs…